Oxford BioDynamics PLC Total Voting Rights (2120J)
December 03 2018 - 4:10AM
UK Regulatory
TIDMOBD
RNS Number : 2120J
Oxford BioDynamics PLC
03 December 2018
OXFORD BIODYNAMICS PLC
TOTAL VOTING RIGHTS
London, 3 December 2018: Oxford BioDynamics Plc (AIM: OBD) (the
"Company")
In conformity with the FCA's Disclosure Guidance and
Transparency Rule 5.6.1, the Company notifies the market that as at
30 November 2018 the Company's total issued share capital consisted
of 92,559,771 ordinary shares with one voting right per share. The
Company does not hold any ordinary shares in Treasury. Therefore,
the total number of voting rights in the Company is 92,559,771.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further details, contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar, CEO
Paul Stockdale, CFO
Shore Capital +44 (0)20 7408 4090
Nominated Advisor and Broker
Stephane Auton
Edward Mansfield
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Advisor
Brett Pollard
Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRGMMGZGFNGRZM
(END) Dow Jones Newswires
December 03, 2018 05:10 ET (10:10 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024